Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.

Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.

The US FDA on 17 February labeled a recall of 2,605 Bellavista 1000 and 1000e series ventilators as class I. Vyaire Medical Inc. had recalled the vents in late December.

No patient injuries have been reported due to the problem, which is now the subject of a voluntary field correction.